Inogen, Inc.
NASDAQ:INGNMedical - Devices
+$0.05 today
- Market cap
- $144.83M
- Beta
- 1.59
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.91
Volume 0.19M
Average 0.33M
INGN Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Inogen, Inc.NASDAQ: INGN
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin narrows to -9.9%
Operating margin was -9.9% in Q1 FY2026, down 0.6 pp from a year earlier. On a trailing-twelve-month basis it was -8.8%, up 1.2 pp year over year. Over 3 fiscal years it widened by 13.9 pp.
Context
- Operating margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 1 analysts of -8.6% for the fiscal year ending Dec 2026, up from -8.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -9.9%+1.5 pp QoQ
- Last fiscal yearDec 2025
- -8.7%+4.0 pp YoY
- LTMMar 2026
- -8.8%+1.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.6 pp | +2.4 pp | +3.0 pp |
| 1 year | +4.0 pp | +0.1 pp | -3.9 pp |
| 3 years | +13.9 pp | +5.6 pp | -8.4 pp |
| 5 years | +9.9 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.7%
- Year-over-year change
- +4.0pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.7% | +4.0pp |
| FY2024 | 2024-12-31 | -12.7% | +22.0pp |
| FY2023 | 2023-12-31 | -34.7% | -12.1pp |
| FY2022 | 2022-12-31 | -22.6% | -25.2pp |
| FY2021 | 2021-12-31 | 2.6% | — |
Operating Margin vs competitors
How INGN compares with its peers on the latest reported figures
- INGN's LTM Mar 2026 operating margin of -8.8% is the 2nd highest of the 10 companies compared; the peer median is -57.5%.
- Its year-over-year change of +1.2 pp is the 6th highest of 10, against a peer median of +2.4 pp.
- Over three fiscal years its change of +13.9 pp compares with a peer median of +67.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 6.4% | -14.2 pp | +64.7 pp | |
| LTM Mar 2026 | -8.8% | +1.2 pp | +13.9 pp | |
| LTM Mar 2026 | -19.2% | +2.4 pp | +39.1 pp | |
| LTM Mar 2026 | -44.8% | +18.8 pp | +69.7 pp | |
| LTM Mar 2026 | -56.9% | +23.6 pp | +83.7 pp | |
| LTM Mar 2026 | -57.5% | -12.1 pp | — | |
| LTM Mar 2026 | -82.7% | -35.0 pp | +19.6 pp | |
| LTM Mar 2026 | -196.6% | +3143.9 pp | +1620.5 pp | |
| LTM Dec 2025 | -466.2% | +36.4 pp | +812.8 pp | |
| LTM Mar 2026 | -19419.6% | -12641.0 pp | -12632.9 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| Peer median (excluding INGN) | -57.5% | +2.4 pp | +67.2 pp | |
Competitors are the stored peer set for INGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 358M | 377.24M | 315.66M | 335.71M | 348.67M |
| Cost of Revenue | 181.52M | 223.71M | 188.96M | 180.96M | 182.78M |
| Gross Profit | 176.48M | 153.53M | 126.7M | 154.74M | 165.89M |
| Gross Margin | 49.3% | 40.7% | 40.1% | 46.1% | 47.6% |
| Research & Development | 16.58M | 21.94M | 20.84M | 21.61M | 19.4M |
| Selling, General & Admin | 150.67M | 164.67M | 182.35M | 175.65M | 165.07M |
| Operating Expenses | 167.24M | 238.78M | 236.09M | 197.26M | 196.1M |
| Depreciation & Amortization | 21.63M | 23.51M | 18.15M | 21M | 20.66M |
| EBITDA | 30.29M | (9.57M) | (58.34M) | (15.47M) | (2.72M) |
| EBITDA Margin | 8.5% | -2.5% | -18.5% | -4.6% | -0.8% |
| Operating Income | 9.24M | (85.24M) | (109.39M) | (42.52M) | (30.21M) |
| Operating Margin | 2.6% | -22.6% | -34.7% | -12.7% | -8.7% |
| Interest Income | 129K | 2.84M | 6.57M | 5.19M | 2.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (581K) | 1.98M | 7.04M | 6.04M | 6.83M |
| Income Before Tax | 8.66M | (83.27M) | (102.34M) | (36.48M) | (23.38M) |
| Pre-Tax Margin | 2.4% | -22.1% | -32.4% | -10.9% | -6.7% |
| Income Tax Expense | 14.99M | 504K | 105K | (588K) | (632K) |
| Net Income | (6.33M) | (83.77M) | (102.45M) | (35.89M) | (22.75M) |
| Net Margin | -1.8% | -22.2% | -32.5% | -10.7% | -6.5% |
| EPS (Basic) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| EPS (Diluted) | (0.28) | (3.67) | (4.42) | (1.52) | (0.85) |
| Weighted Avg Shares | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
| Weighted Avg Shares (Diluted) | 22.49M | 22.85M | 23.18M | 23.65M | 27.18M |
Inogen, Inc.
NASDAQ:INGN
Intrinsic Alpha fair value
Locked
Current Price
$5.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.